Motion Sickness Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||922022|
|出版日期||內容資訊||英文 115 Pages
|全球暈車藥市場:成長，趨勢，及預測 Motion Sickness Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 115 Pages||
The motion sickness treatment market studied was anticipated to grow with a CAGR of nearly 3.0% during the forecast period. There are certain factors that are driving the market growth, including a rise in the number of travelers across the globe and increased incidences of cardiovascular diseases in the geriatric population which majorly cause motion sickness. For instance, according to United Nations World Tourism Organization (UNWTO), international tourist arrivals increased by 5.4% in 2018 compared to 2017 and this tendency is expected to continue throughout the forecast period which demands higher requirements for motion sickness treatment globally. Also, ongoing research activities in motion sickness drug development and delivery systems are likely to increase the availability of OTC drugs for motion sickness treatment.
Motion sickness is a common disorder characterized by a set of symptoms such as dizziness, nausea, and fatigue experienced by a person while traveling due to differences in impulses in the eyes, other body tissues, and sensory receptors. Motion sickness is most commonly observed among children and geriatrics. It is experienced by about 50% to 70% of travelers and even while playing virtual reality (VR) games.
Anticholinergic Treatment Segment By Treatment Type is Expected to Hold the Largest Market Share in the Motion Sickness Treatment Market
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to account for the largest share of the motion sickness treatment. This is due to increased tourism in the U.S. and preference for highly expensive prescription drugs directly contributes to a significant share of revenue in the region. For instance, according to the UNWTO, in 2018, nearly 52 million International tourists travel from America to Europe resultant in a higher demand for the motion sickness treatment market in the region.
Followed by North America, Europe contributed to the second largest market share owing to a rise in a number of travelers all over the world, increased research activities and investors to develop novel drug delivery systems for motion sickness treatment accounts for the highest revenue.
Globally, the Asia - Pacific region is expected to witness the fastest growth in the forthcoming years due to the presence of global and local players in the Chinese and Indian markets. An increased number of domestic and international travelers are expected to boost the global motion sickness treatment market in the Asia Pacific.
The motion sickness treatment market is moderately competitive and consists of several major players. Few of the major players currently dominating the market are implementing various development strategies such as making mergers and acquisitions, entering into partnerships and thus, expanding their footprint globally. For instance, WellSpring Pharmaceutical Corporation acquired BONINE, an OTC drug for motion sickness, from Prestige Brands Holdings and added to its U.S. OTC nausea franchise, consolidated their market positions in the U.S. While some of the major players are launching simplified and more novel drug delivery systems compared to that of commercial innovator drugs. For example, Caleb Pharmaceuticals introduced the first matrix-type transdermal patch, Ariel TDDS Patch for the treatment of motion sickness. It is much simpler than that of Transderm Scop, the first commercial scopolamine TDDS. Thus, ongoing research activities and developments directly fuel the growth of the global motion sickness treatment market. In terms of market share, the prominent companies that are currently dominating the market are Prestige Consumer Healthcare Inc, WellSpring Pharmaceutical Corporation, Caleb Pharmaceuticals Inc, Myungmoon Pharm Co. LTD, and Reliefband Technologies LLC